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a b s t r a c t
A 27-year-old woman with frequent implantable cardioverter deﬁbrillator (ICD) shocks related to
catecholaminergic polymorphic ventricular tachycardia (VT) experienced aborted sudden death due to
incessant polymorphic VT despite the administration of beta-blockers, verapamil, and ﬂecainide. Catheter
ablation failed to suppress the polymorphic VT. Based on the temporary efﬁcacy of the local anesthetic
administered at the left and right cervical sympathetic nerves to suppress VT under an isoproterenol
infusion, stepwise, bilateral thoracoscopic sympathectomy was performed. Postoperatively, no further VT or
syncopal episodes were documented under ICD telemetry. Bilateral thoracoscopic sympathectomy may be
an alternative for patients with drug-refractory catecholaminergic polymorphic VT.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
was ﬁrst reported in 1975 and is characterized by exercise- or
emotional stress-induced polymorphic ventricular tachyarrhyth-
mias, syncope, or sudden cardiac death [1,2]. Although β-blockers,
verapamil, and Na-channel blockers have been used to suppress
VT in these patients, their symptoms persist and prognosis
remains poor [3]. We describe a case of aborted sudden death
due to catecholaminergic polymorphic VT in a patient who had
received treatment with antiarrhythmic agents and an implanta-
ble cardioverter deﬁbrillator (ICD) in whom VT could be success-
fully suppressed after bilateral thoracoscopic sympathectomy.
2. Case report
A 27-year-old woman diagnosed with CPVT, who did not have a
family history of sudden cardiac death, and was implanted with a
dual chamber ICD at another institution 11 years previously for
recurrent syncopal episodes during exercise and emotional stress
was followed up by our hospital. She had experienced frequent
(nearly 5 times per year) ICD shocks (Secura™, Medtronic, Min-
neapolis, USA) related to ventricular ﬁbrillation or atrial tachycar-
dia (AT) with a rapid ventricular response under the oral
administration of antiarrhythmic agents, including bisoprolol
5 mg/day, verapamil 240 mg/day, and ﬂecainide 150 mg/day
(3 mg/kg), which were her maximally tolerable doses because of
general fatigue due to hypotension. During the follow-up, she was
resuscitated from aborted sudden death due to incessant poly-
morphic VT documented on electrocardiography. Deep sedation
with intratracheal intubation was effective in suppressing VT, and
fortunately, no brain damage occurred after hypothermia therapy.
The initial premature ventricular contractions (PVCs), which
triggered the polymorphic VT, were conﬁrmed to have mainly
two morphologies: left bundle branch block with a superior axis
(PVC1) and right bundle branch block with an inferior axis (PVC2)
under an isoproterenol infusion (ISP) at 1.5 mg/min. We conﬁrmed
that the maximum beat runs of VT could be suppressed to only
couplets of PVCs by a left stellate ganglion blockade using
lidocaine as the local anesthesic, under the same dose of the ISP
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infusion (Fig. 1). First, we attempted catheter ablation targeting
those initial PVCs. The right ventricular inferior wall under the
tricuspid valve (PVC1: the local bipolar ventricular potential
preceded the onset of the PVC by 20 ms without any discrete
pre-potentials, and a good pacemap of the QRS conﬁguration was
obtained) and left ventricular outﬂow tract immediately under the
aortic valve of the left coronary cusp (PVC2: a good pacemap of the
QRS conﬁguration was obtained) were considered as the origins of
the PVCs, and ablation at those sites with 25–30 W suppressed the
PVCs under the same ISP infusion dose of 1.5 mg/min. However,
ablation at the above sites was ineffective under an infusion of ISP
of 3.0 mg/min because a maximum of 8 beat runs of a non-
sustained polymorphic VT (NSPVT) with an average cycle length
of 237 ms was induced. In addition, treadmill exercise testing
(10.2 Mets) after the ablation revealed the occurrence of bidirec-
tional polymorphic VPCs. Those PVCs were mainly of two types,
such as a left bundle branch block with a superior axis and an
inferior axis type, and the morphologies were different from those
before the ablation. Although VT did not recur clinically, the
catheter ablation was considered insufﬁcient to prevent any future
VT recurrence. Therefore, after written informed consent was
obtained, the patient underwent left thoracoscopic sympathect-
omy from the lower one-third of the left stellate ganglion to the
Th4 level under general anesthesia (Fig. 2) based on the effective-
ness of the left stellate ganglion local blockade and according to a
previous report [4]. After that operation, VT was no longer
inducible until 10.2 Mets of exercise via treadmill exercise testing,
but was easily induced over 11.2 Mets of exercise. We next
evaluated the efﬁcacy of the local right stellate ganglion blockade,
and found that this dramatically suppressed the polymorphic VT
under an ISP 3.0 mg/min infusion. Based on this result, she under-
went an additional right thoracoscopic sympathectomy from the
lower one-third of the right stellate ganglion to the Th5 level. After
the operation, VT could no longer be induced for up to 11.2 Mets of
exercise (Table 1: each number after NSPVT indicates maximum
beat runs). The heart rate was lower (93 bpm vs. 103 bpm) during
the same 10.2 Mets of exercise, and AT inducibility was suppressed
to a greater extent during the exercise (11.2 Mets vs. 12.9 Mets)
after right thoracoscopic sympathectomy than after left thoraco-
scopic sympathectomy alone. Complications such as left ptosis and
decreased sweating of the left hand (Horner's syndrome) persisted
during the follow-up after left thoracoscopic sympathectomy, but
the symptoms could be well tolerated without any complaints of
severity. The patient was discharged from our hospital under the
oral administration of bisoprolol 5 mg/day and verapamil 240 mg/
day. Nine months after bilateral sympathectomy, she felt an ICD
shock immediately after bathing but did not experience any
syncope. ICD telemetry revealed an inappropriate shock for an
AT with a rapid ventricular response and some PVCs without any
polymorphic VT (Fig. 3B), but no ICD shocks have been recorded
after that last event up to the 12 months of follow-up.
3. Discussion
CPVT is an inherited arrhythmia syndrome, characterized by
polymorphic ventricular tachycardia induced by adrenergic stress
and caused by mutations of the cardiac ryanodine receptors or
calsequestrin gene without any structural heart disease. Beta
blockers are currently a class I indication for the treatment of
clinically diagnosed patients [5]. Watanabe et al. discovered that
ﬂecainide prevents arrhythmias in a mouse model of CPVT by
inhibiting the cardiac ryanodine receptor-mediated Ca2þ release
and directly targets the underlying molecular defect. In addition,
Fig. 1. (A) Polymorphic VT (maximally ﬁve beat runs) was frequently induced by an ISP infusion (1.5 mg/min). The heart rate (P–P interval during sinus rhythm) was 134 bpm.
We immediately discontinued the ISP infusion because wewere concerned about the occurrence of life-threatening sustained polymorphic VT. (B) VT could be suppressed up
to only couplets of PVCs after the local left stellate ganglion blockade under the same dose of ISP infusion. The heart rate was similar to that mentioned above.
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ﬂecainide completely prevented CPVT in two patients who had
remained highly symptomatic with conventional drug therapy [6].
van der Werf also reported that ﬂecainide resulted in either a
partial (n¼8) or complete (n¼14) suppression of exercise-induced
ventricular arrhythmias in 22 of 29 patients. In addition, no
patients experienced any worsening of their exercise-induced
ventricular arrhythmias [7]. However, our case had experienced
aborted sudden death due to incessant polymorphic VT under the
administration of ﬂecainide. The detection interval of ventricular
ﬁbrillation (VF) and VT were more than 250 beats/min and 200–
250 beats/min, respectively, at that time, and no VT/VF episodes
were recorded in ICD telemetry. An incessant form of VT with a
cycle length less than 200 beats/min may be the reason why an
ICD shock was not delivered for this event. In this patient, the
detection interval for both VT and VF should have been more than
200beats/min to prevent inappropriate ICD shocks for AT with a
rapid ventricular response. However, this setting may have been
the reason for the under detection of VT combined with a
prolonged VT cycle length caused by the ﬂecainide 150 mg/day
(3 mg/kg) in this patient. For that reason, we did not increase the
dose of ﬂecainide after that severe clinical event. On the other
hand, even if the ICD could have detected VT and delivered the
shocks, it may have led to catecholamine release, resulting in
further electrical storm [8].
The electrocardiographic characteristics and efﬁcacy of
catheter ablation of CPVT have been reported. Sumitomo et al.
reported that the initiating focus originated from the right
ventricular outﬂow tract in 15 cases, in the right ventricular
outﬂow tract and left ventricular outﬂow tract in one case, in
the right ventricular apex in six cases, in the right ventricular
apex and right ventricular outﬂow tract in three cases, in the left
ventricular apex in one case, and in the left ventricular apex and
right ventricular outﬂow tract in one case. The mean CPVT heart
rate was 192 beats/min (range, 150–250 beats/min), with most
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Fig. 2. Demonstration of left thoracoscopic sympathectomy. (A) Thoracoscopic view during the operation. (B) The resected ganglions between the lower one-third of the left
stellate ganglion and the Th4 level.
Table 1
Isoproterenol and treadmill exercise testing.
ISP 1.5 μg/min ISP 3.0 μg/min TET 10.2 Mets TET 11.2 Mets TET 12.9 Mets
Control NSPVT 5#1
SR 134 bpm
LSG block PVC couplet
SR 134 bpm
Postablation PVC (–) NSPVT 8#2 PVC
SR 134 bpm AT 250 bpm SR 111 bpm
PostLSG1/3-Th4 resection PVC (–) NSPVT 6#3
SR 103 bpm AT 135 bpm
RSG block PVC (–) PVC couplet
SR 120 bpm SR 140 bpm
PostRSG1/3-Th5 resection PVC (–) PVC (–) PVC
SR 93 bpm SR 97 bpm AT 107 bpm
ISP: isoproterenol; TET: treadmill exercise testing; LSG: left stellate ganglion; RSG: right stellate ganglion; NSPVT: maximum beat runs of non-sustained polymorphic
ventricular tachycardia; SR: heart rate during sinus rhythm; AT: heart rate during AT; # indicates the average cycle length of the NSPVT: #1¼312 ms, #2¼237 ms, #3¼400 ms.
RA 
RV 
RA 
RV 
detection
detection
Average bpm: A/V = 182/188 
Average bpm: A/V = 222/316 
1 sec
Fig. 3. Demonstration of the intra-cardiac electrograms recorded on the ICD
telemetry. (A) Before the sympathectomy, dual tachycardias with polymorphic
ventricular and atrial tachycardia were frequently recorded. The VT detection
interval was 4200 bpm and the VF detection interval was 4250 bpm. (B) Only
one event was recorded after the left and right sympathectomies. The VT and VF
detection intervals were changed to 4150 bpm and 4200 bpm, respectively, after
bilateral sympathectomy to prevent missing any severe VT events. Note that no
polymorphic ventricular tachycardia was detected during the atrial tachycardia
with a rapid ventricular response.
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CPVT cases being nonsustained. Catheter ablation of the initiat-
ing focus of the CPVT was attempted in two cases but was
unsuccessful [3]. On the other hand, they also reported a case
with CPVT in which pulmonary vein isolation was performed for
AF. The Holter monitor recordings demonstrated a major
decrease in the clinical episodes of AF and VTs in association
with a reduced high-frequency (HF) component and ratio of the
low-frequency (LF) component power to the HF component (LF/
HF) after pulmonary vein isolation [9]. Kaneshiro et al. reported
a successful catheter ablation of bidirectional PVCs triggering
ventricular ﬁbrillation in CPVT with RyR2 mutation [10]. They
could eliminate the PVCs by catheter ablation in the left
ventricular inferoseptal area near the posteromedial papillary
muscle and the left coronary cusp. Neither episodes of syncope
nor ICD therapies occurred during 16-months of follow-up
under the administration of bisoprorol 2.5 mg QD. We per-
formed mapping and catheter ablation of the PVCs triggering
the polymorphic VT. The right ventricular inferior wall under
the tricuspid valve and left ventricular outﬂow tract under the
aortic valve of the left coronary cusp were considered as origins
of the PVCs, but the efﬁcacy of the ablation was limited. Because
PVCs were induced according to the dose of catecholamine
administered and polymorphic VTs could be easily induced,
activation mapping and ablation of all the PVCs may have been
insufﬁcient in our case. Although our patient also simulta-
neously had AT with a rapid ventricular response and VT, we
did not perform pulmonary vein isolation because polymorphic
VT is not usually associated with AT (Fig. 1A). As Kaneshiro et al.
concluded, more cases and a longer-term observation are
mandatory to clarify the effectiveness and safety of catheter
ablation for CPVT.
Sympathetic denervation is considered as one of the alternative
treatment options for CPVT. Wilde et al. reported the long-term
efﬁcacy of surgical left cardiac sympathetic denervation in three
young adults with CPVT, all of whom had symptoms before the
procedure and were symptom-free later [11]. They suggested the
important advantages of left cardiac sympathetic denervation. Once
the procedure is performed, the effects are permanent, because
preganglionic denervation precludes reinnervation. Denervation
does not result in the limitations that occur with medical therapies
such as incomplete compliance, especially among teenagers. Scott
et al. reported the successful treatment of CPVT with bilateral
thoracoscopic sympathectomy in a young woman with multiple
ICD-related complications that ﬁnally needed to be explanted due
to an ongoing infection. During 4 years of follow-up since the
sympathectomy, the patient has been free from any further synco-
pal episodes without any re-implantation of an ICD [12]. The
authors mentioned that sympathectomy may have a useful role as
an adjunctive therapy in CPVT, as beta-blockade was not completely
effective and long-term ICD use was associated with potential
complications. Vaseghi et al. reported the efﬁcacy of left (n¼14)
and bilateral (n¼27) cardiac sympathetic denervation (CSD) in 41
patients with VT storms. Although both showed beneﬁcial effects
with VT suppression, bilateral CSD resulted in greater ICD shock-
free survival compared to left CSD alone [13]. In our case, the
patient ﬁrst underwent left thoracoscopic sympathectomy, which
was effectively suppressed polymorphic VTs under 10.2 Mets of
treadmill exercise testing, but did not suppress these VTs over
11.2 Mets of exercise. Based on the dramatic efﬁcacy of the right
stellate ganglion blockade using local anesthesia to suppress the
polymorphic VT under an ISP infusion, the patient also underwent
right thoracoscopic sympathectomy. After the last procedure, no VT
events or syncope was documented for a follow-up of 21 months,
except for one inappropriate ICD shock due to AT with a rapid
ventricular response nine months after bilateral sympathectomy.
Interestingly, dual tachycardias with polymorphic VT and AT were
frequently recorded simultaneously before the sympathectomy
(Fig. 3A), but no polymorphic VT was detected during the last AT
event (Fig. 3B). This phenomenon can be explained in light of the
following literature. A number of antiarrhythmic effects after
sympathectomy are mediated by a reduction in the amount of
intracardiac noradrenaline release. This includes an increase in the
threshold for the induction of VF and an increase in ventricular
refractoriness [14,15].
We hereby described an initial case of drug- and ablation-
refractory CPVT that was successfully suppressed by step-wise,
bilateral thoracoscopic sympathectomy in an Asia-Paciﬁc country.
Although PVCs occurred under 11.2 Mets of exercise, neither
couplets nor polymorphic VTs could be induced, which suggested
that the bilateral thoracoscopic sympathectomy in this patient
suppressed the maximum beat runs of polymorphic VT. The reason
why our patient not only needed left but also right sympathect-
omy to suppress the CPVT was not clear. The anatomical distribu-
tion of cardiac sympathetic nerves and its role in the induction of
cardiac arrhythmias may differ between patients. In addition, it
would be better to evaluate the efﬁcacy of bilateral thoracoscopic
sympathectomy on autonomic nervous activity by heart rate
variability. However, this was difﬁcult in our patient because heart
rate was dependent almost solely on the atrial pacing rhythm
under full medication.
4. Conclusion
Thoracoscopic bilateral sympathectomy may be an alternative
therapy for patients with drug-refractory CPVT.
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